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Abstract
Recent advances in genomics technologies have spurred unprecedented efforts in genome and exome re-sequencing
aiming to unravel the genetic component of rare and complex disorders. While in rare disorders this allowed the
identification of novel causal genes, the missing heritability paradox in complex diseases remains so far elusive. Despite
rapid advances of next-generation sequencing, both the technology and the analysis of the data it produces are in its
infancy. At present there is abundant knowledge pertaining to the role of rare single nucleotide variants (SNVs) in rare
disorders and of common SNVs in common disorders. Although the 1,000 genome project has clearly highlighted the
prevalence of rare variants and more complex variants (e.g. insertions, deletions), their role in disease is as yet far from
elucidated. We set out to analyse the properties of sequence variants identified in a comprehensive collection of exome
re-sequencing studies performed on samples from patients affected by a broad range of complex and rare diseases
(N = 173). Given the known potential for Loss of Function (LoF) variants to be false positive, we performed an extensive
validation of the common, rare and private LoF variants identified, which indicated that most of the private and rare variants
identified were indeed true, while common novel variants had a significantly higher false positive rate. Our results indicated
a strong enrichment of very low-frequency insertion/deletion variants, so far under-investigated, which might be difficult to
capture with low coverage and imputation approaches and for which most of study designs would be under-powered.
These insertions and deletions might play a significant role in disease genetics, contributing specifically to the underlining
rare and private variation predicted to be discovered through next generation sequencing.
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Introduction
The progressively decreasing costs of next generation sequenc-
ing, combined with targeted approaches such as exome sequenc-
ing, have allowed rapid deployment of this technology in a variety
of contexts: population studies, familial cases of disease, as well as
complex diseases. Exome sequencing represents a cost-effective
strategy for identification of causal variants, especially in a clinical
context [1] [2], where clinical information and familial history
may aid in the identification of the causal genetic variant within a
coding region.
Several population-based studies have so far provided a general
overview of variation in the human genome. The 1,000 Genomes
Consortium has provided the first whole genome overview in
control populations indicating that the majority of SNVs are
already found in dbSNP (87.28%) [3]. Similar results were
reported in smaller scale studies comparing 10 disease genomes
and 10 control genomes [4]. Another study on exome sequencing
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on a control population of 200 individuals from Denmark, with an
average coverage of 126 fold, showed an excess of SNPs
annotated as low-frequency (2–5%) non-synonymous coding
variants in a control population [5].
One of the first published exome sequencing studies focused on
a rare dominantly inherited disorder, Freeman–Sheldon syndrome
[6]. This study was the first of many studies to show the potential
for direct identification of the causal gene of monogenic disorders
by using exome sequencing. In the past two years more than 180
papers have been published addressing specific genetic conditions
using exome sequencing in patients with an inherited disorder
[7,8,9], producing a substantial amount of data to confirm that an
average exome will contain 20,283 (6523) variants, 5 of which are
usually nonsense and novel [7].
Despite the surge in published studies relating to familial cases,
there are many issues pertaining to genome re-sequencing which
remain unexplored. As far as complex disease genetics is
concerned, exome sequencing is still in its infancy. Although
several labs are involved in sequencing complex disease cases,
results published so far have not succeeded in identifying major
causal variants of high frequency in patients under investigation,
but rather single rare variants affecting a minority of the patients
significantly [10]. Additionally, most of the studies conducted so
far on specific diseases focus on single nucleotide variants, rather
than insertion/deletion variants (INDELs). This is due in part to
the fact that insertion/deletion bioinformatics analysis pipelines
are still being refined [11,12], and additional efforts for their
proper annotation is needed [13].
It has been shown, however, that this type of variation is clearly
widespread and probably under-characterized: recent work
identified 2 million such variants with relatively limited overlap
with data from current 1000 Genome releases [14,15]. The same
study also estimated that 65% of the INDEL variants found in
coding regions are rare, and a significant number of SNPs from
existing genome-wide association studies (GWAS) are in linkage
disequilibrium (LD) with the INDELs identified, suggesting that
coding INDELs are likely to be responsible for a substantial
amount of phenotypic diversity and disease genetics in humans
[14]. Similar data have been shown by the 1000 Genomes Exon
Pilot project group, which indicated that most INDELs are often
found at low frequency [16].
A substantial contribution, has been made recently by
MacArthur et al, who systematically reviewed 1,000 Genome
loss-of-function (LoF) variants, which they expected to be
particularly enriched for artefacts compared to the other
polymorphisms [17]. They identified 1,147 high confidence LoF
variants out of 2,807 screened, 326 of which were INDELs. Most
of these variants are rare, being subject to purifying selection, and
only 43% survived an accurate and aggressive filtering step. Their
validation rate seems to be inversely correlated with variant
frequency (as also shown by the 81% validation rate provided by
the Exon Pilot project group for INDELs which are usually of low
frequency [16]), and with their position in the gene (those at the 39
end being the most enriched for false positives). Although the study
does not investigate sequence variation and LoF variant validation
in disease samples, it provides an indirect analysis of the potential
role of these variants in complex disease. This is achieved by
imputing in seven different disease datasets, the genotypes for 417
LoF SNVs and INDELs. This analysis, however, yielded no
overall excess of association signal for LoF variants as compared to
other coding variants (no data is provided for INDEL variants
specifically) [18] suggesting a minor role for common loss-of-
function variants in disease genetics.
On the basis of a wide collaboration across University College
London, Cardiff University and San Raffaele Scientific Institute,
in this study we present a focused investigation of INDEL variation
across exomes sequenced at 476 average coverage from a wide
range of clinical patient samples, from both familial and sporadic
clinically verified complex disease cases, and an extensive
validation of the common, rare and private INDEL variants
identified. On average, within our study, a patient exome will
present 82 novel INDELs. In total, 5,749 unique novel INDELs
were identified in this study, most of which are very rare.
Importantly, while common variants present high false positive
rates in line with variant validation issues presented by other
groups, almost all private variants validated, and a significant
proportion of rare variants, were found to be true. Our study
indicates a potential role for private and rare LoF INDELs in
disease genetics.
Results
We processed 173 exomes from different diseases (comprising
33 familial cases with Mendelian inheritance and 140 sporadic/
complex disease cases), using Novoalign (www.novocraft.com,
previously compared on in silico data by Krawitz et al. [11]),
Dindel and our own annotation script based on the ENSEMBL
API (see Material and Methods). On average for each exome we
obtained 36.6 millions 76 bp paired-end reads (+-2.8 millions), of
which 32.1 millions mapped in proper pairs on the genome (+-2.7
millions), resulting in an average coverage of target regions of 476
(+-3.86). With the same pipeline we also processed the Exome
dataset of the 1000 Genome Consortium, to be used for our
comparative analysis (Figure 1).
The dataset of disease exomes revealed an average of 20,332
SNPs which are already described in ENSEMBL, an average of
162 SNPs described only in the October 2010 release of the 1000
Genome project, and an average of 517 novel SNPs specific to our
disease exome study. In total, 52,981 unique novel SNPs were
identified in this study (see Text S1, section 3.2). Although our
SNV data are consistent with those recently published by
MacArthur and colleagues, here we focus our analysis on INDELs,
thus far, largely under-investigated.
Characteristics of INDELs
Figure 2A in the paper shows a comparison of the density
distributions of the Indel size called with Dindel on our 174-
exomes sample set, those recently released by the 1000genome
Consortium and those already present in the ENSEMBL database:
each of these distributions takes into account the INDELs falling
within our exome capture regions only. None of our calls exceeds
15 bp, and most of them have a length lower than 6 bp.
Comparing our INDELS to those found in ENSEMBL it becomes
apparent that ENSEMBL contains at much higher frequency
INDELs of 1 bp of length as compared to the other two datasets
(probably due to historical screens for single base mutations), while
for all other lengths the 1,000genomes dataset includes relatively
more variations than our dataset at this length: since the same
caller was used (Dindel), this could be due to our choice of aligner
(Novoalign), which might map less efficiently reads overlapping
INDELs longer than 15 bp, as well as the use of whole genome
sequencing data as opposed to exome sequencing data. This
observation, coupled with the observation above that INDELs are
likely to play a significant role in understanding the genetics of
complex disease, indicate that improvement of sequence variation
screening (by either sequencing whole genomes, improvements in
read length and improvement of INDEL detection pipelines) is
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likely to allow a much more comprehensive characterization of the
role of sequence variation in disease.
The correlation between the size of the INDEL alleles identified
in our dataset and those described in ENSEMBL is high for
insertions, but less so for deletions (r2 = 0.9221 for insertions and
0.4213 for deletions, both with p value,2* 10216, Figure 2B). This
highlights the difficulties the community faces in characterizing
deletions appropriately, as well as the issues that it faces in using
the information available in public databases to correctly
characterize this type of variants. This issue is made even more
challenging when taking into account that for most of the INDELs
called there are multiple and different alleles, which are often not
described in ENSEMBL.
Since most of the called INDELs appear to correlate with the
size of those present in the database, even when multiple records
are present in each window, we investigated the relationship with
the distance between the start position of the INDELs called in our
dataset and the closest one in ENSEMBL (Figure 2C). In order to
do so, we extended the window size to 100 base pairs flanking our
call and within the multiple ENSEMBL hits in our window, we
selected the closest one of similar length if present and plotted its
distance from the sequenced INDEL. The majority of described
variations fall within 5 bp from the starting point of the INDEL
called in our dataset, and most of them within 10 bp. Notably,
most of the variations appear to be found only downstream of our
starting point: Dindel tries to reposition each INDEL as far to the
59 end (lower coordinates) as possible, given the same alternative
haplotype (Albers C. personal communication) and left-aligning of
reported INDEL position is emerging as a standard. This
phenomenon is likely due to the fact that existing databases have
been built much before these standards emerged and the 1,000
Genome efforts.
We calculated the non-reference allele(s) frequency in our
dataset and categorized the effect of each INDEL using the
ENSEMBL API. While INDELs which are already described in
existing databases such as dbSNP follow a distribution across a
higher range of frequencies (Figure 3A), most of the insertions and
deletions recently described by the 1,000 Genome project and
those which are entirely novel to our dataset are distributed on
lower frequencies (Figure 3A and Table 1, Table S1 for
comparison with other datasets counts). These characteristics are
in line with the most recent studies published by other groups, and
in particular Mills et al [14] and MacArthur et al [18].
Low rate of false positives for rare and private INDELs
Taking into account data shown in other studies indicating that
LoF variants may be enriched for artefacts, we proceeded to
validate systematically 160 insertion/deletions in a different set of
samples. By comparing the variants called in the two datasets and
we were able to identify 82 INDELs which are common between
the two sample sets (Table S2), and 78 INDELs which are private
(Table S3). All of these variants were then validated using Sanger
Figure 1. Rationale. We processed 162 exomes from different diseases (comprising 22 familial cases with mendelian inheritance and 140 sporadic/
complex disease cases), and 11 samples from a different set of familial rare disorders with Mendelian inheritance, to be used for validation, with our
pipeline characterised by Novoalign, Dindel and our own annotation script based on the ENSEMBL API. With the same pipeline we processed 21
samples from the Exome dataset of the 1000 Genome Consortium, to be used for comparison. 1000 Genome Consortium INDEL release October 2010
was also annotated with the same script, and annotation data have been compared. INDELs called in the two UCL datasets have been compared to
identify common and private ones, and select a representative set to be validated with Sanger sequencing.
doi:10.1371/journal.pone.0051292.g001
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sequencing, both in DNA samples where they were originally
called, as well as in samples where they were meant to be absent,
in order to check for both false positives and false negatives.
Overall the validation rate for the INDELs called using our
pipeline was higher than shown in previous studies, i.e. 88.13%
(Table 2). Interestingly, private INDELs presented a significantly
higher validation rate (96.15%) as compared to the ones present in
more than one sample (80.49%, Chi-squared = 7.9378, p-val-
ue = 0.004841). The high validation rate of private INDELs is
likely due to the use of high coverage sequencing in the analysis
and highlights an important portion of very rare variants that are
likely to be either detected with higher false positive rates, or
missed entirely by low coverage population sequencing.
If we analyse these data in more detail, and we take into account
the frequency of the variants by dividing them into common (non-
reference allele frequency equal or higher than 0.05), rare
(frequency lower than 0.05) and private as shown in Figure 3B,
the validation rate is significantly different between the three
groups (Chi-squared= 44.4844, p-value = 2.189*10210). We car-
ried out our validation phase by genotyping the INDELs in two
samples: one reported by NGS to carry the variant, and one
reported as homozygous for the reference. This choice allowed us
to check for false negatives. None of the samples expected to be
reference reported insertion/deletions in Sanger sequencing, and
was therefore confirmed as negative. In line with previous
observations, most of the INDELs which did not validate displayed
a high frequency in our patients, with some exceptions (i.e. a large
frameshift insertion on chromosome 7 that will require further
investigation (Table S2).
We finally performed a comparison between the distribution of
the predicted consequences in our patients samples and the
samples from 1000 Genomes we re-analysed: the analysis (Figure 4)
highlighted a higher proportion of frameshift INDELs in our
samples (Test S1, section 4.3; Table S4 and Figure S2). Although
such a finding might be influenced by several differences between
the two samples sets, we were unable to pinpoint any specific
difference which could explain this result.
Discussion
We present here the first overview of INDEL variations found in
exomes performed at an average 476coverage on patient samples
from a variety of confirmed sporadic and familial cases of disease.
The pipeline we used results in a good validation rate, as it actually
yields better validation rate (88.1% against 81.3%) than previously
published validation results [16]. Our analysis highlights a
considerable number of variants which are not included in the
1,000 genome release. The choice of algorithms, thresholds, and
filters could have an impact on our findings and the rate of false
positive LoF variants identified but the results indicated the
parameters adopted perform in line with other published pipelines.
For this reason we decided to re-analyze the 1,000 Genome data
using our pipeline, to ensure the comparison was accurate, and
correct for the total number of variants called per sample.
Moreover, we also tested the impact of using the GATK pipeline,
which provided very similar results and did not eliminate the
common false positive alleles that were identified.
In the analysis of 173 exomes it is clear that most variation
identified within exome disease study as novel is of a ‘‘private’’
nature or of very low frequency. This confirms that the more we
will sequence, the more novel alleles we will identify, as previously
suggested [14]. On the other hand, despite the 1,000 Genome
Project effort, we are still able to identify in our disease dataset
some novel, validated, high frequency alleles. Part of this may be
due to the choice of the aligner and caller combination, as our re-
analysis of 1000 Genome exome shows, but on the other hand this
result also indicates that obtaining and sharing more data from
disease exome studies will help to have a better picture of sequence
variation in disease.
While INDELs with very high frequency across different
patients tend to be artifacts as indicated by our validation analysis,
we noticed some high frequency INDELs which were not
identified by the 1,000 G project, and might be due to differences
in the bioinformatics pipeline employed. On a similar note, we
identify known high frequency INDELs in our patient exomes,
although they are putatively damaging. These findings highlight
that the search for variants that are potentially disease-causing
cannot be simplified to searching for merely ‘‘novel damaging
variation’’, since known variants can be causative, and damaging
variants can be tolerated, as was well described recently [13,18].
The presence of a considerable number of loss of function
insertion-deletions in our samples would suggest that the genetics
of complex disease are, indeed a compound effect of several rare
and private more complex variants across the genome. To
establish this with greater certainty, and also to understand to
what extent it is a property of many diseases as opposed to specific
ones, comprehensive frequency information from large control
and disease populations will be of fundamental importance.
The finding that our samples are particularly enriched in
validated novel and low-frequency variants is important because
most of the study designs and latest statistical methods addressing
the role of rare variants would still be under-powered for private or
very low frequency insertion-deletions. Low-coverage and impu-
tation methodologies would not be effective and high coverage
sequencing would still be required to capture them [19,20,21].
Interestingly, INDELs and in particular frameshift INDELs,
stand out for a variety of reasons as being frequent in our patient
disease exomes. It is tempting to speculate that, if common LoF
variants do not play a major role in complex disease as suggested
recently [18], low frequency and, in particular, private INDELs
might contribute quite significantly to as yet uncharacterized
genetics of disease. In particular they might confirm the
expectations from next generation sequencing to discover rare
and private variants that explain and characterise individual
variability in health and diseases (Figure S3), as our data suggest.
Our analysis indicates, however that many challenges still exist,
however, in assessing this type of variation accurately, given the
current lack of frequency information in large control and disease
populations, as well as their variability in length, multiple potential
alleles, and position which often makes it difficult to assign a highly
confident identity to an INDEL variant.
Figure 2. INDELs characteristics. Figure 2A shows a comparison of the length of INDEL variants called in our patients, and those available in the
same capture regions in the ENSEMBL database and in the 1000 Genome Consortium release. The plot shows a higher presence of 1 bp insertion/
deletions in ENSEMBL, and an increased size detection capability in 1000 Genome data, obtained from whole genome sequencing. Figure 2B shows a
correlation of the INDELs already described in ENSEMBL between the size of the variant sequenced in our samples and the length reported in the
database (r2 = 0.9221 for insertions and 0.4213 for deletions, both with p value,2* 10216). Figure 2C shows the distribution of the distance (i.e.
difference between start positions) between the INDELs as they were called by Dindel on our data, or as released by 1000 Genome Consortium, and
the corresponding ones present in ENSEMBL.
doi:10.1371/journal.pone.0051292.g002
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Figure 3. INDELs frequency and validation. Figure 3A plots the non-reference allele frequency of INDELs called in our samples, divided in three
categories: those already described in ENSEMBL, those described only in the released of 1000 Genome and those completely novel to our dataset,
most of which are rare. Figure 3B shows the counts of validated INDELs according to the following frequency categories: common (non reference
allele frequency equal or higher than 0.05), rare (frequency lower than 0.05) and private. The validation rate is significantly different in the three
groups (Chi-squared= 44.4844, p-value= 2.189*10210).
doi:10.1371/journal.pone.0051292.g003
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The need for appropriate control populations is highlighted by
our comparison with 1,000 Genome samples. The differences we
found, although interesting, might be affected by several biases
difficult to identify and address despite the use of the same analysis
pipeline: differences in capture technology and read length, in
coverage of the coding regions, the ethnicity of the samples and
mixed ancestry or other unknown technical bias. Such biases are
difficult to remove, despite our careful corrections.
Table 2. Validation of variants.
A) Common INDELs
Validated Not Validated Validation Rate
Novel 24 13 64.86%
Newly released 42 3 93.33%
Total 66 16 80.49%
B) Private INDELs
Validated Not Validated Validation Rate
Novel 73 3 96.05%
Newly released 2 0 100.00%
Total 75 3 96.15%
Total 141 19 88.13%
The table provides a summary of the validation results, both for the INDELs common to the two sequencing datasets used, and the private ones. All INDELs sent for
validation were classified as ‘‘novel’’ according to dbSNP 131 and the 1000 Genome Consortium release October 2010. During the validation phase new data have been
released by 1000 Genome (November 11th 2011): INDELs have been here categorised according to this latest release, to be considered as an independent confirmation.
Figure 4. INDELs consequences comparison. This boxplot details the differences in the comparison of the distributions of consequence
proportions per sample between our disease exomes data and 1000 Genome exomes. Significant differences, calculated with a non parametric
Wilcoxon test of independent samples, have been highlighted with a star.
doi:10.1371/journal.pone.0051292.g004
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Importantly we were only able to identify relatively short
INDELs, while the identification of much larger INDELs which
are relatively common is highly affected by the choice of existing
bioinformatics pipelines. Thus, our disease exome study provides a
pointer to what might be the most interesting source of sequence
variation in disease, insertions and deletions, and at the same time
highlights many of the limits that we currently face in fully
assessing this type of sequence variation. If, despite our limitations,
this type of sequence variation emerges as a significant component,
we can only be brought to imagine that if we had more
comprehensive data (e.g. full genome sequences with longer
sequence read lengths), we would see this component play an even
more significant role.
On average we identified 15 rare frameshift INDELs in each
patient, suggesting an important role for these variations. Our
group of patients comes from different origins and certainly
ethnicity may influence the discovery of novel variants, or change
their frequency, and these issues should be taken into account
when expanding and characterising internal collections.
Clearly there are some substantial reproducible artefacts using
current sequencing technologies and bioinformatics pipelines,
since certain common, high quality false positive variants recur in
a large number of samples. The use of filters and automatic
procedures certainly aids in reducing the observed enrichment of
false positives in LOF calls [17] together with other filters recently
suggested (location in the transcript, gene etc.) [18], but still does
not bring validation rate to acceptable standards (e.g. greater than
95%). Interestingly, however, our study indicates that this is not
the case for rare and private INDEL variants, which have
remarkably high validation rate.
Once we excluded technical artefacts, the identification of
novel, rare or private, potentially damaging variants across such a
diverse group of diseases opens additional areas of investigation:
despite their predicted effect those variants may not be causative.
The observation that the consequences of novel INDELs have a
higher variability across these disease patients seems to reinforce
their role in this scenario. Integration of larger whole genome and
exome datasets from both patients and controls will provide more
clues with regards to the relationship between these variants across
the genome and their link with disease.
Interestingly, although our sample collection contains samples
from both sporadic cases of disease (140) and familial cases of
disease (22), all of the results shown, in terms of allele
consequences and frequencies are similar in both datasets.
Removing the familial cases from the dataset had no significant
impact on the frequencies observed for neither SNPs nor INDELs
across biological consequences, dataset categories, or MAF
categories. This raises some interesting questions, since so far
most publications focused on rare familial disorders and thus the
discovery of rare, damaging causative SNPs was expected. Our
study, however, indicates that rare and potentially damaging
INDEL variation is a common feature also in exomes from
sporadic cases of complex disease and that, in particular,
frameshift coding insertions and deletions are a specific and
significant feature also in sporadic cases of complex disease.
Materials and Methods
Samples
The samples used in this analysis come from several different
research projects: neurological disorders (Alzheimer’s, Parkinson’s
disease, epilepsy, ataxia), muscular dystrophy, retinal dystrophy,
liver cirrhosis, eczema and erythrokeratoderma.
Sample preparation
Samples for the 162 exome dataset were sequenced using the
HiSeq 2000, following Illumina supplied protocols, with 100 bp
paired end kits.
Samples for the 11 exomes validation dataset were prepared by
GOSgene at the UCL Institute of Child Health and sequenced
using the Genome Analyzer IIx (UCL Genomics facility, at the
University College London), following Illumina supplied protocols,
with 76 bp paired end kits.
The sequencing data of the patients dataset was produced at the
Beijing Genomics Institute and analyzed by the UCL Geno-
mics.The sequencing data used as a validation dataset was
produced and analyzed by the UCL Genomics facility, at
University College London and GOSgene.
Quality control
After the sequencing reactions were complete, the Illumina
analysis pipeline was used to process the raw sequencing data
(Bustard and Gerald) and produce fastq format files. The quality of
the sequencing runs were assessed by evaluating the percentage of
clusters passing the filter, and by running the FastQC software and
evaluating read length and base quality profiles, GC content,
average GC content per base, average base content per read
position, and checking for any indication of over-represented
sequences.
Alignment
Once the raw sequence data was assessed for quality, the reads
were aligned to a human reference genome (GRC37 release,
downloaded from the ENSEMBL database). Novoalign performed
gapped alignments and was launched with the additional hard
clipping option based on read base quality (-H) and the default
adaptor removal option (-a).
Coverage and alignment summary
The alignment summary is reported by using in-house perl
scripts, that count the bitwise flags for the sam files produced
during the alignment steps.
The coverage along the genome has been calculated using
BEDtools (GenomeCoverageBed function), without omitting zero
values.
In-house perl scripts have been used to summarize these data in
mean, median, standard deviation and percentiles across the
captured regions.
Indel calling with Dindel
Dindel version 1.01 has been used to call INDELs from
Novoalign alignments. The default parameters have been used.
Dindel requires a BAM file containing the read-alignments as
input. It then extracts candidate INDELs from the BAM file, and
realigns the reads to candidate haplotypes consisting of these
candidate INDELs in windows of ,120 bp. If there is sufficient
evidence for an alternative haplotype to the reference, it will call
an INDEL and produces a VCF file.
Annotation
The annotation of both SNPs and Indel variants has been
performed with an in-house perl script that integrates with the
ENSEMBL API and queries the database on all available features,
formats them in summary files, compares the calls with the
1000genome calls and classifies the variants (algorithm in Figure
S1).
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A more detailed explanation can be found in Text S1, section
5.2.
Comparisons and reporting
The visualization and comparison of the different length and
frequency distributions, as well as the predicted effect and calls
have been done using R (www.r-project.org) and the graphical
package ‘‘ggplot2’’.
Statistical analysis
In order to compare the proportion of different consequences
across our disease dataset and the 1000 Genome exome dataset,
and account for differences in the total number of variants called
in each individual, we converted the counts in percentage per
individual, and compared the distributions between the individuals
of the two groups by using a non parametric Wilcoxon test of
independent samples. The tests have been performed using R,
basic ‘‘stats’’ package.
Validation of the INDELs
5 ng of each DNA sample were amplified in a 20 ml reaction
mixture containing 0.2 mM of each dNTP (Takara), 16Titanium
Taq PCR Buffer (Clontech), 0.256Titanium Taq DNA Polymer-
ase (Clontech) and 0.2 mM of forward and reverse primers
designed to specifically amplify each DNA fragment containing
a putative indel. The PCR program included an initial step of
denaturation at 95uC for 1 minute followed by 35 cycles of
amplification characterized by the following profile: 95uC for 300,
60uC for 300, 68uC for 300 and a final extension step at 68uC for
3 minutes. Each PCR product was purified with AgencourtH
AMPureH XP (Beckman Coulter) magnetic beads and subse-
quently sequenced by standard dideoxy-sequencing on Applied
Biosystem 3730 with both forward and reverse primers. Sequence
data obtained from each PCR fragment were aligned to the
corresponding reference sequences with the software Sequencher
4.9 (Gene Codes).
Supporting Information
Figure S1 INDELs annotation. The figure shows the decision
process adopted in our annotation algorithm, in determining if an
INDEL has been previously described in ENSEMBL or in the
1000 Genome release. Priority is given to variants of the same
length, and sequence, followed by the closest variant, if present
within a 10 bp window from the start position of the sequenced
variant.
(EPS)
Figure S2 INDEL consequences comparison. In this
picture, the proportion of different consequences is represented.
In the first column, the INDELs available in ENSEMBL and
within our capture regions are reported. The second column
reports the same annotation performed on the variants released by
1000 Genome Consortium. The other groups of columns compare
the consequence proportions of our analysis on 1000 Genome
exome data and our patients’ exomes.
(EPS)
Figure S3 Consequences: sample level variability. The
figure shows an overview per sample of the proportion of different
consequences for SNPs (A) and INDELs (B).
(EPS)
Table S1 INDELs counts. The table summarises the average
counts (and standard deviation) of each consequence per category
of dataset. Our calls have been divided among those already
described in ENSEMBL, those described only in the latest release
of 1000 Genome and those that are novel. The table reports the
counts for the annotation of the variants available in ENSEMBL
and positioned in our capture regions, the same annotation for the
variants released by 1000 Genome and the comparison between
our analysis of 1000 Genome data and our dataset.
(XLSX)
Table S2 Common INDELs validation. The table lists the
INDELs common between several samples, with higher frequency
in our dataset, which have been validated in the 11 samples used
for validation with Sanger sequencing. The column ‘‘nonRef_-
MAF’’ reports the frequency of non-reference alleles in our
samples, the column ‘‘sequence’’ indicates whether Sanger
sequence reported the same sequence as called in NGS data,
and the column ‘‘latest1000G’’ indicates if the variant has been
called in the release of November 2011 of the 1000 Genome
Consortium.
(XLSX)
Table S3 Private INDELs validation. The table lists the
INDELs private to single samples, which have been validated in
the 11 samples used for validation with Sanger sequencing. The
column ‘‘nonRef_MAF’’ reports the frequency of non-reference
alleles in our samples, the column ‘‘sequence’’ indicates whether
Sanger sequence reported the same sequence as called in NGS
data, and the column ‘‘latest1000G’’ indicates if the variant has
been called in the release of November 2011 of the 1000 Genome
Consortium.
(XLSX)
Table S4 Comparison of INDELs consequence propor-
tions. The table reports the average percentage of each
consequence within category of called INDELs, and within the
data available in ENSEMBL and released by the 1000 Genomes
Consortium. Significance values are calculated comparing the two
distributions of per sample percentages, within each category, with
a Wilcoxon two independent samples test.
(XLSX)
Text S1 Supplementary analysis and description of the
detailed methodology and workflow.
(DOCX)
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